Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7945380 | 0.98 | ALDH1A1 (0.34) | ALDH1A1POLBMAPTHTTSMN1; SMN2 | |
| SCHEMBL2895440 | 0.98 | ALDH1A1 (0.34) | ALDH1A1POLBMAPTHTTSMN1; SMN2 | |
| Bromide SCHEMBL30100053 | 0.96 | ALDH1A1 (0.33) | ALDH1A1POLBMAPTHTTSMN1; SMN2 | |
| SCHEMBL30787938 | 0.87 | ALDH1A1 (0.36) | ALDH1A1POLBMAPTHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL12502204 | 0.81 | MYC (0.32) | — | |
| SCHEMBL9382328 | 0.78 | GAA (0.36) | ALDH1A1POLBMAPTHTTKDM4E | |
| SCHEMBL7729842 | 0.76 | MAPT (0.34) | ALDH1A1POLBMAPTNPSR1KDM4E | |
| SCHEMBL28532318 | 0.74 | ALDH1A1 (0.32) | ALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL22685877 | 0.71 | TYR (0.34) | HTTNPSR1 | |
| SCHEMBL5740940 | 0.70 | ALDH1A1 (0.39) | ALDH1A1POLBMAPTHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507292-A1 | USE OF SILYLATED FORMIATES AS HYDROSILANE EQUIVALENTS | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2019-07-10 | — | — | EP | claimed |
| CN-118119412-A | Purified signal enhanced contrast agent for magnetic resonance imaging | 马克斯·普朗克科学促进协会 | 2024-05-31 | — | — | CN | disclosed |
| CN-117794644-A | Iron-catalyzed metathesis polymerization of olefins | 耶达研究与发展有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023167321-A1 | MECHANOCHEMICAL REACTION ADDITIVE, MECHANOCHEMICAL METHOD, LIGAND COMPOUND, AND COMPLEX | 国立大学法人北海道大学 | 2023-09-07 | — | — | WO | disclosed |
| US-11718584-B2 | Process for the synthesis anthranilic diamide compounds and intermediates thereof | PI INDUSTRIES LTD. (IN) | 2023-08-08 | — | — | US | disclosed |
| CN-114728981-A | Condensed polycyclic aromatic compound | 日本化药株式会社 | 2022-07-08 | — | — | CN | disclosed |
| US-20220185782-A1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI INDUSTRIES LTD. (IN) | 2022-06-16 | — | — | US | disclosed |
| CN-114269754-A | Condensed polycyclic aromatic compound | 日本化药株式会社 | 2022-04-01 | — | — | CN | disclosed |
| EP-3927685-A1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | PI Industries Ltd. (IN) | 2021-12-29 | — | — | EP | disclosed |
| CN-113614063-A | Method for synthesizing anthranilamide compound and intermediate thereof | PI工业有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3374363-A1 | METHOD FOR PREPARING METHOXYBORANES AND FOR PRODUCING METHANOL | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2018-09-19 | — | — | EP | disclosed |
| EP-3374364-A1 | USE OF BORON FORMATES FOR REDUCING UNSATURATED ORGANIC FUNCTIONS | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2018-09-19 | — | — | EP | disclosed |
| CN-106488920-A | The preparation method of antiviral compound | 吉利德制药有限责任公司 | 2017-03-08 | — | — | CN | disclosed |
| CN-103717587-B | Manufacture the method for benzo [B] thiophene compound | OTSUKA PHARMACEUTICAL CO.,LTD. (JP) | 2016-02-10 | — | — | CN | disclosed |
| CN-102725269-B | synthetic intermediate of oxazole compound and preparation method thereof | OTSUKA PHARMA CO LTD | 2015-03-25 | — | — | CN | disclosed |
| CN-103717587-A | Method for producing benzo[B]thiophene compound | OTSUKA PHARMA CO LTD | 2014-04-09 | — | — | CN | disclosed |
| EP-2528896-A1 | SYNTHETIC INTERMEDIATE OF OXAZOLE COMPOUND AND METHOD FOR PRODUCING THE SAME | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2049535-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008016184-A1 | ALPHA-CARBOLINE DERIVATIVES AND METHODS FOR PREPARATION THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718584-B2 | Process for the synthesis anthranilic diamide compounds and intermediates thereof | DAO, DDC, QDPR | HRH3 627/4885ALDH1A1 914/4885POLB 1080/4885 |
| US-20220185782-A1 | A PROCESS FOR THE SYNTHESIS ANTHRANILIC DIAMIDE COMPOUNDS AND INTERMEDIATES THEREOF | DAO, DDC, QDPR | HRH3 659/4885ALDH1A1 1089/4885POLB 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.